Fredag 27 December | 14:04:54 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-05 08:00 Kvartalsrapport 2025-Q3
2025-08-21 08:00 Kvartalsrapport 2025-Q2
2025-05-22 N/A Årsstämma
2025-05-08 08:00 Kvartalsrapport 2025-Q1
2025-02-27 08:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-23 - X-dag ordinarie utdelning ONCO 0.00 SEK
2024-05-22 - Årsstämma
2024-04-15 - Extra Bolagsstämma 2024
2024-02-27 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-10 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning ONCO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-09-23 - Extra Bolagsstämma 2022
2022-08-11 - Kvartalsrapport 2022-Q2
2022-06-28 - Årsstämma
2022-05-20 - X-dag ordinarie utdelning ONCO 0.00 SEK
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning ONCO 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-12-04 - Extra Bolagsstämma 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning ONCO 0.00 SEK
2020-05-26 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-12-17 - Extra Bolagsstämma 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning ONCO 0.00 SEK
2019-05-21 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-13 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning ONCO 0.00 SEK
2018-05-17 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-18 - Årsstämma
2017-05-18 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Oncopeptides är ett bioteknikbolag som utvecklar läkemedel för svårbehandlade hematologiska sjukdomar. Bolaget använder sin PDC-plattform för att ta fram peptidlänkade läkemedel som selektivt levererar cellgifter in i cancerceller. Bolaget har läkemedel för kommersialisering, och har flera läkemedelskandidater under utveckling. Oncopeptides huvudkontor ligger i Stockholm.
2024-04-17 14:10:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

On 13 March 2024, Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) announced that the Board of Directors has decided to carry out a fully guaranteed rights issue of approximately SEK 314 million before deduction of costs related to the rights issue (the “Rights Issue”).

The prospectus relating to the Rights Issue has today, 17 April 2024, been approved and registered by the Swedish Financial Supervisory Authority and is available on Oncopeptides’ website, https://oncopeptides.com/en/investors/share-issues/rights-issue-may-2024/ and on Carnegie Investment Bank AB (publ)’s website, www.carnegie.se. The prospectus will also be made available on the Swedish Financial Supervisory Authority’s website, www.fi.se.
 
Shareholders with nominee registered holdings are referred to their respective nominees for specific information and instructions. Shareholders with directly registered holdings receive information by mail and can find subscription forms with and without subscription rights on Oncopeptides’ and Carnegie's websites.
 
The subscription period starts on 19 April 2024, and runs up until 3 May 2024. The complete timetable for the rights issue is available in the prospectus and on Oncopeptides’ website, https://oncopeptides.com/en/investors/share-issues/rights-issue-may-2024/.
 
The Company has been informed that three investors have undertaken to acquire and subscribe for all subscription rights that Industrifonden is entitled to receive per its existing holding, corresponding to 8,285,258 subscription rights.

Advisors
Carnegie Investment Bank AB (publ), DNB Markets, a part of DNB Bank ASA, Sweden Branch and Zonda Partners act as Joint Bookrunners in connection with the Rights Issue. Advokatfirman Vinge KB is legal adviser to the Company and Baker McKenzie is legal adviser to the Joint Bookrunners in connection with the Rights Issue.